X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration, SK bioscience will supply the antigen utilized by its typhoid conjugate vaccine, SKYTyhpoid to develop a novel vaccine-delivery device combination product using Vaxxas’ high-density microarray patch (HD-MAP) platform technology.
Lead Product(s): Typhoid Conjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: SK Bioscience
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 24, 2023
Details:
The funding will support the IND-enabling studies and a first-in-human clinical study for a potentially second generation typhoid vaccine delivered by Vaxxas’ proprietary high-density microarray patch platform technology.
Lead Product(s): Typhoid Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Wellcome
Deal Size: $3.6 million Upfront Cash: Undisclosed
Deal Type: Funding August 23, 2023
Details:
HexaPro, a second-generation version of the spike protein used in all major U.S. approved COVID-19 vaccines, which was modified to be more stable and immunogenic than its predecessor, giving potential coverage of all known SARS-CoV-2 variants.
Lead Product(s): HexaPro
Therapeutic Area: Infections and Infectious Diseases Product Name: HexaPro
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
The vaccine being delivered by the Vaxxas HD-MAP in this Phase I clinical trial is a commercially available seasonal flu vaccine (IIV4) targeting four significant strains of the influenza virus.
Lead Product(s): Inactivated Seasonal Influenza Vaccine Quadrivalent
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Details:
The financing will accelerate the clinical program for Vaxxas’ COVID-19 vaccine patch candidate which is based upon the company’s proprietary HD-MAP delivery of HexaPro, a second-generation version of the spike protein used in all major US-approved COVID-19 vaccines.
Lead Product(s): HexaPro
Therapeutic Area: Infections and Infectious Diseases Product Name: HexaPro
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: OneVentures
Deal Size: $23.0 million Upfront Cash: Undisclosed
Deal Type: Financing December 05, 2022
Details:
HexaPro, a highly stabilized protein that is designed to mimic the structure of the spike protein on the surface of the coronavirus to train the human immune system to recognize and fight SARS-CoV-2 infection.
Lead Product(s): HexaPro
Therapeutic Area: Infections and Infectious Diseases Product Name: HexaPro
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2022
Details:
The license obtained by Vaxxas from the United States’ National Institutes of Health, enables Vaxxas to create the first needle-free, room-temperature stable, SARS-CoV-2 spike subunit vaccine (HexaPro) patch to enter clinical studies.
Lead Product(s): Recombinant SARS-CoV-2 Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: HexaPro
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 23, 2022
Details:
Vaccination via HD-MAP induced enhanced T-cell and spike-specific antibody responses as compared to needle-and-syringe delivery of the same vaccine in an animal model.
Lead Product(s): HD-MAP
Therapeutic Area: Infections and Infectious Diseases Product Name: HD-MAP
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021
Details:
Under the collaboration agreement, originally signed in 2012, through the exercise of this option MSD gains exclusive worldwide rights to develop and commercialize an undisclosed vaccine utilizing Vaxxas’ HD-MAP technology.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: Merck & Co
Deal Size: $12.0 million Upfront Cash: Undisclosed
Deal Type: Agreement May 28, 2020
Details:
The new funding will be used for IND-enabling studies and a first-in-human clinical study for measles and rubella vaccination using Vaxxas’ advanced HD-MAP platform.
Lead Product(s): Measles vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding March 17, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
